Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-04-30T15:39:47.056Z Has data issue: false hasContentIssue false
  • English
  • Français

The Mechanism of the Combined Treatment of Depression with Iproniazid and Reserpine

Published online by Cambridge University Press:  08 February 2018

M. Assael ,
F. Gabay ,
N. Khazan ,
F. G. Sulman  and
H. Z. Winnik
M. Assael
Affiliation:
Talbieh Psychiatric Hospital and the Department of Applied Pharmacology of the Hebrew University-Hadassah Medical and Pharmacy Schools, Jerusalem, Israel
F. Gabay
Affiliation:
Talbieh Psychiatric Hospital and the Department of Applied Pharmacology of the Hebrew University-Hadassah Medical and Pharmacy Schools, Jerusalem, Israel
N. Khazan
Affiliation:
Talbieh Psychiatric Hospital and the Department of Applied Pharmacology of the Hebrew University-Hadassah Medical and Pharmacy Schools, Jerusalem, Israel
F. G. Sulman
Affiliation:
Talbieh Psychiatric Hospital and the Department of Applied Pharmacology of the Hebrew University-Hadassah Medical and Pharmacy Schools, Jerusalem, Israel
H. Z. Winnik
Affiliation:
Talbieh Psychiatric Hospital and the Department of Applied Pharmacology of the Hebrew University-Hadassah Medical and Pharmacy Schools, Jerusalem, Israel
Get access Rights & Permissions [Opens in a new window]

Extract

The beneficial effect of monoamine oxidase blockers on depressive states has been established. Their therapeutic effect has been assessed at ranging between 60 and 80 per cent. of all cases treated. We have tried to improve on this rate by combined treatment with iproniazid and reserpine, a combination which has been used in experimental animals by Chessin et al. (1, 2) and Brodie et al. (3). The results of our treatment will be briefly described in this paper.

Type
Original Articles
Information
Journal of Mental Science , Volume 106 , Issue 444 , July 1960 , pp. 1021 - 1026
Copyright
Copyright © Royal College of Psychiatrists, 1960 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Chessin, M., Dubnick, B., Kramer, E. R., and Scott, C. C., Federation Proc., 1956, 15 (Part 1), 409.Google Scholar
2 Idem , Kramer, E. R., and Scott, C. C., J. Pharmacol. and Exper. Therap., 1957, 119, 453–460.Google Scholar
3 Brodie, B. B., and Shore, P. A., Ann. N. Y. Acad. Sci., 1957, 66, 631.Google Scholar
4 Kaffman, M., and Winnik, H. Z., Harefuah (Journal of the Israel Medical Association), 1959, 56, 167–172.Google Scholar
5 Sulman, F. G., Lancet, 1952, i, 1161.Google Scholar
6 Khazan, N., and Sulman, F. G. (in press).Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.